Cuorips Inc.
Notice regarding the issuance of new shares through a third-party allotment
issuance of 619,700 new shares through a third-party allotment at 4,841 yen per share to raise approximately 3,000 million yen. The funds will be allocated to R&D for next-generation cardiac cell sheets, catheter therapies, internal regeneration factor inducers, and MSC development, as well as preparation and execution of future clinical trials. Allottee is JICVGI Opportunity Fund No. 1 Investment Business Type Limited Liability Partnership, dilution about 7.5%, payment deadline September 28, 2026.
Key Figures
- New shares: 619,700 shares
- Paid-in amount: 4,841 yen
- Total funding: 2,999,967,700 yen
AI要約
Overview of the offering and funding purpose
Qualips will issue 619,700 new shares through a third-party allotment, raising approximately 300 million yen. The paid-in price is 4,841 yen per share, and the funds will be invested in R&D expenditure including rehart (R Heart) and clinical trial preparation costs, as well as outsourcing costs, to support growth drivers. The allottees are JICVGI Opportunity Fund No. 1 Investment Business Type LLC, with estimated dilution of about 7.5%.
Outlook and significance of capital policy
The fundraising will support continued growth of ReHeart domestic sales and accelerate pipeline development, including U.S. expansion of next-generation cardiac cell sheets, catheter therapies, internal regeneration factor inducers, and MSCs. The plan is to allocate funds mainly to costs for clinical trial preparation and execution, with a view to medium- to long-term increases in corporate value.
Qualips Co., Ltd.
Company overview · Stock price · Financial data · All IR
